Aclaris Therapeutics (ACRS) Free Cash Flow (2014 - 2026)

Aclaris Therapeutics' Free Cash Flow history runs 13 years deep, the most recent figure standing at -$18.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 39.0% year-over-year to -$18.2 million in Q1 2026; TTM through Mar 2026 was -$52.3 million, a 323.89% decrease from a year earlier, with the FY2025 full-year figure at -$47.2 million, down 133.83% from the prior year.
• Free Cash Flow declined to -$18.2 million in Q1 2026 per ACRS's latest filing, from -$13.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $22.0 million in Q3 2024 and bottomed at -$26.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$13.2 million (2025), against an average of -$13.7 million.
• Across the five-year window, Free Cash Flow tumbled 208.01% in 2023 and jumped 189.65% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$18.6 million in 2022, then jumped by 58.72% to -$7.7 million in 2023, then fell by 16.17% to -$8.9 million in 2024, then sank by 48.02% to -$13.2 million in 2025, then plunged by 37.63% to -$18.2 million in 2026.
• Per Business Quant, the three latest ACRS Free Cash Flow figures stand at -$18.2 million (Q1 2026), -$13.2 million (Q4 2025), and -$10.9 million (Q3 2025).